RTI Surgical (RTIX) 10-Q 2 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 24, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'RTI SURGICAL, INC.	'
Entity Central Index Key	'0001100441	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	56,623,563

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$15,465	$18,721
Accounts receivable-less allowances of $564 at March 31, 2014 and $492 at December 31, 2013	32,038	31,752
Inventories-net	104,546	106,126
Prepaid and other current assets	6,173	5,483
Deferred tax assets-net	25,165	24,577
Total current assets	183,387	186,659
Property, plant and equipment-net	76,257	74,738
Deferred tax assets-net	6,497	5,452
Goodwill	54,887	54,887
Other intangible assets-net	32,787	33,786
Other assets-net	14,228	14,332
Total assets	368,043	369,854
Current Liabilities:	'	'
Accounts payable	21,561	23,231
Accrued expenses	20,635	22,478
Deferred tax liabilities	195	195
Current portion of deferred revenue	4,870	5,109
Current portion of short and long-term obligations	4,073	1,344
Total current liabilities	51,334	52,357
Long-term obligations-less current portion	70,194	67,706
Other long-term liabilities	13,239	13,446
Deferred revenue	17,195	18,755
Total liabilities	151,962	152,264
Preferred stock Series A, $.001 par value: 5,000,000 shares authorized; 50,000 shares issued and outstanding	50,333	49,537
Stockholders' equity:	'	'
Common stock, $.001 par value: 150,000,000 shares authorized; 56,620,563 and 56,388,063 shares issued and outstanding, respectively	57	56
Additional paid-in capital	415,503	415,426
Accumulated other comprehensive loss	-763	-812
Accumulated deficit	-248,860	-246,550
Less treasury stock, 180,898 and 146,957 shares, at cost	-189	-67
Total stockholders' equity	165,748	168,053
Total liabilities and stockholders' equity	$368,043	$369,854

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, allowances	$564	$492
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	50,000	50,000
Preferred stock, shares outstanding	50,000	50,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	56,620,563	56,620,563
Common stock, shares outstanding	56,388,063	56,388,063
Treasury stock, shares	180,898	146,957

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Revenues	$60,745	$40,422
Costs of processing and distribution	34,547	21,226
Gross profit	26,198	19,196
Expenses:	'	'
Marketing, general and administrative	25,854	15,023
Research and development	3,832	3,111
Total operating expenses	29,686	18,134
Operating (loss) income	-3,488	1,062
Other (expense) income:	'	'
Interest expense	-336	'
Interest income	3	6
Foreign exchange loss	-22	-6
Total other (expense) income-net	-355	'
(Loss) income before income tax benefit	-3,843	1,062
Income tax benefit	1,533	400
Net (loss) income	-2,310	1,462
Convertible preferred dividend	-750	'
Net (loss) income applicable to common shares	-3,060	1,462
Other comprehensive (loss) income:	'	'
Unrealized foreign currency translation gain (loss)	49	-611
Comprehensive (loss) income	($3,011)	$851
Net (loss) income per common share-basic	($0.05)	$0.03
Net (loss) income per common share-diluted	($0.05)	$0.03
Weighted average shares outstanding-basic	56,451,646	56,022,389
Weighted average shares outstanding-diluted	56,451,646	56,290,110

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net (loss) income	($2,310)	$1,462
Adjustments to reconcile net (loss) income to net cash used in operating activities:	'	'
Depreciation and amortization expense	3,664	2,028
Provision for bad debts and product returns	53	31
Provision for inventory write-downs	1,314	757
Amortization of deferred revenue	-1,799	-2,915
Deferred income tax provision (benefit)	-1,039	-954
Stock-based compensation	490	485
Other	15	210
Change in assets and liabilities:	'	'
Accounts receivable	-299	111
Inventories	1,081	-2,828
Accounts payable	-650	-1,271
Accrued expenses	-2,970	-7,417
Deferred revenue	'	3,000
Other operating assets and liabilities	-857	-762
Net cash used in operating activities	-3,307	-8,063
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-4,936	-2,708
Patent and acquired intangible asset costs	-217	-98
Net cash used in investing activities	-5,153	-2,806
Cash flows from financing activities:	'	'
Proceeds from exercise of common stock options	292	85
Proceeds from long-term obligations	4,000	'
Net proceeds from short-term obligations	1,233	'
Payments on long-term obligations	-20	-82
Other financing activities	-122	-23
Net cash provided by (used in) financing activities	5,383	-20
Effect of exchange rate changes on cash and cash equivalents	-179	-5
Net decrease in cash and cash equivalents	-3,256	-10,894
Cash and cash equivalents, beginning of period	18,721	49,696
Cash and cash equivalents, end of period	15,465	38,802
Supplemental cash flow disclosure:	'	'
Cash paid for interest	351	2
Cash paid for income taxes, net of refunds	-79	2,137
Change in accrual for purchases of property, plant and equipment	1,059	950
Change in accrual for acquired intangible asset costs	'	$79

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)

Total

Series A Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-In Capital [Member]

Additional Paid-In Capital [Member]

Accumulated Other Comprehensive Loss [Member]

Accumulated Other Comprehensive Loss [Member]

Accumulated Deficit [Member]

Accumulated Deficit [Member]

Treasury Stock [Member]

Treasury Stock [Member]

In Thousands

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Beginning Balance at Dec. 31, 2013

$168,053

'

$56

'

$415,426

'

($812)

'

($246,550)

'

($67)

'

Net loss

-2,310

'

'

'

'

'

'

'

-2,310

'

'

'

Foreign currency translation adjustment

49

'

'

'

'

'

49

'

'

'

'

'

Exercise of common stock options

292

'

1

'

291

'

'

'

'

'

'

'

Stock-based compensation

490

'

'

'

490

'

'

'

'

'

'

'

Purchase of treasury stock

-122

'

'

'

'

'

'

'

'

'

-122

'

Amortization of preferred stock Series A issuance costs

-123

-46

'

'

'

-46

'

'

'

'

'

'

Preferred stock Series A dividend

'

-750

'

'

'

-750

'

'

'

'

'

'

Change in tax benefit from stock- based compensation

92

'

'

'

92

'

'

'

'

'

'

'

Ending Balance at Mar. 31, 2014

$165,748

'

$57

'

$415,503

'

($763)

'

($248,860)

'

($189)

'

Operations_and_Organization

Operations and Organization	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Operations and Organization	'
	1. Operations and Organization
	The company is a leader in the use of natural tissues, metals and synthetics to produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes. The Company processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing its proprietary BIOCLEANSE® and TUTOPLAST® sterilization processes, for distribution to hospitals and surgeons. The Company processes natural tissue at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany and manufactures metal and synthetic products in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and products in all 50 states and in over 45 countries worldwide.

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	2. Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, which the Company considers necessary for a fair presentation of the results of operations for the periods shown. The condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X, and, therefore, do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations, comprehensive income and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The condensed consolidated financial statements include the accounts of RTI Surgical, Inc. and its wholly owned subsidiaries, Pioneer Surgical Technology, Inc. (“Pioneer”), Tutogen Medical, Inc. (“TMI”), RTI Surgical, Inc. – Cardiovascular (inactive), Biological Recovery Group, Inc. (inactive) and RTI Services, Inc. (inactive). The condensed consolidated financial statements also include the accounts of RTI Donor Services, Inc. (“RTIDS”), which is a controlled entity.

Merger_with_Pioneer_Surgical_T

Merger with Pioneer Surgical Technology, Inc.	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Merger with Pioneer Surgical Technology, Inc.	'
	3. Merger with Pioneer Surgical Technology, Inc.
	On July 16, 2013, the Company completed its acquisition of Pioneer. Under the terms of the merger agreement dated June 12, 2013, the Company acquired Pioneer for $126,307 in cash. The transaction was funded through a combination of cash on hand, a new credit facility and a concurrent private placement of convertible preferred equity. The Company obtained from Toronto-Dominion Bank, N.A., TD Securities “USA” LLC (“TD Bank”) and Regions Bank, a 5 year, $80,000 senior secured facility, which includes a $60,000 term loan and a $20,000 revolving credit facility, that matures on July 16, 2018 with a variable interest rate between 100 and 300 basis points in excess of the one month London Interbank Offered Rate (“LIBOR”). The $20,000 revolving credit facility replaced the Company’s previous $15,000 U.S. credit facility.
	Additionally, the Company received $50,000 in gross proceeds from a private placement of convertible preferred equity to WSHP Biologics Holdings, LLC, an affiliate of Water Street Healthcare Partners, a leading healthcare-focused private equity firm (“Water Street”). The convertible preferred stock is convertible into shares of the Company’s common stock. The convertible preferred stock will also accrue dividends at a rate of 6% per year. In 2013, the Company capitalized $1,989 in financing costs associated with the preferred stock issuance and the debt issuance.
	The Company has accounted for the acquisition of Pioneer under Accounting Standards Codification (“ASC”) 805, Business Combinations. Pioneer’s results of operations are included in the consolidated financial statements for periods ending after July 16, 2013, the acquisition date.
	The purchase price was financed as follows:
	Cash proceeds from term loan		$	60,000
	Net cash proceeds from preferred share issuance			48,710
	Cash from RTI Surgical			17,597
	Total purchase price		$	126,307
	The table below represents an allocation of the total consideration to Pioneer’s tangible and intangible assets and liabilities based on management’s preliminary estimate of their respective fair values as of July 16, 2013.
	Inventories		$	35,972
	Accounts receivable			10,567
	Other current assets			6,059
	Property, plant and equipment			15,258
	Other assets			13,260
	Current liabilities			(10,893	)
	Other long-term liabilities			(19,841	)
	Net tangible assets acquired			50,382
	Other intangible assets			23,100
	Goodwill			52,825
	Total net assets acquired		$	126,307
	Total net assets acquired as of July 16, 2013 are all part of the Company’s only operating segment. Fair values are based on management’s preliminary estimates and assumptions including variations of the income approach, the cost approach and the market approach.
	The Company believes that the acquisition of Pioneer offers the potential for substantial strategic and financial benefits. The transaction will enhance the Company’s existing core competency in biologics processing with the addition of Pioneer’s core competency in metals and synthetics. The Company believes the acquisition will enhance stockholder value through, among other things, enabling the Company to capitalize on the following strategic advantages and opportunities:
		•		Diversification of its implant portfolio.
		•		Expansion of our direct distribution and marketing organizations.
		•		Enhancement of our current international business.
		•		Improvement of our margin profile and revenue growth opportunities.
	These potential benefits resulted in the Company paying a premium for Pioneer resulting in the recognition of goodwill. The $52,825 of goodwill was assigned to the Company’s only operating segment.
	The fair value of receivables acquired is $10,567, with the gross contractual amount being $11,712, of which $1,145 was not expected to be collected.
	The following unaudited pro forma information shows the results of the Company’s operations as though the acquisition had occurred as of the beginning of that period (in thousands, except per share data):
			For the Three
			Months Ended
			March 31, 2013
	Revenues		$	62,450
	Net income			477
	Basic net income per share			0.01
	Diluted net income per share			0.01
	The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the merger taken place as of the beginning of the periods presented, or the results that may occur in the future.
	These amounts have been calculated to reflect the additional depreciation, amortization and interest expense that would have been incurred assuming the fair value of adjustments and borrowings occurred on January 1, 2013, together with the consequential tax effects. In addition, these amounts exclude costs incurred which are directly attributable to the acquisition, and which do not have a continuing impact on the combined companies’ operating results.
	The Company expects to complete its analysis of the purchase price allocation by the third quarter of 2014.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	4. Stock-Based Compensation
	The Company has five stock-based compensation plans under which employees, consultants and outside directors have received stock options and restricted stock awards. The Company’s policy is to grant stock options at an exercise price equal to 100% of the market value of a share of common stock at closing on the date of the grant. Stock options generally have ten-year contractual terms and vest over a one to five year period from the date of grant. The Company’s policy is to grant restricted stock awards at a fair value equal to 100% of the market value of a share of common stock at closing on the date of the grant. Restricted stock awards generally vest over one to three year periods.
	1998 Stock Option Plan, 2004 Equity Incentive Plan and 2010 Equity Incentive Plan – The Company adopted equity incentive plans in 1998 (the “1998 Plan”), 2004 (the “2004 Plan”) and 2010 (the “2010 Plan”), which provide for the grant of incentive and nonqualified stock options and restricted stock to key employees, including officers and directors of the Company and consultants and advisors. The 1998 Plan, 2004 Plan and 2010 Plan allow for up to 4,406,400, 2,000,000 and 5,000,000 shares, respectively, of common stock to be issued with respect to awards granted. New stock options may no longer be awarded under the 1998 Plan.
	TMI 1996 Stock Option Plan and TMI 2006 Incentive and Non-Statutory Stock Option Plan – In connection with the merger with TMI, the Company assumed the TMI 1996 Stock Option Plan and the TMI 2006 Incentive and Non-Statutory Stock Option Plan (“TMI Plans”). The TMI Plans allow for 4,880,000 and 1,830,000 shares of common stock, respectively, which may be issued with respect to stock options granted to former TMI employees or employees of the Company hired subsequent to the TMI acquisition. New stock options may no longer be awarded under the TMI 1996 Stock Option Plan.
	Stock Options
	As of March 31, 2014, there was $3,139 of total unrecognized stock-based compensation related to nonvested stock options. That expense is expected to be recognized over a weighted-average period of 3.57 years.
	Stock options outstanding, exercisable and available for grant at March 31, 2014 are summarized as follows:
		Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life (Years)
	Outstanding at January 1, 2014		5,518,604		$	4.63
	Granted		913,500			3.78
	Exercised		(90,500	)		3.23
	Forfeited or expired		(98,500	)		5.28
	Outstanding at March 31, 2014		6,243,104		$	4.51		5.87	$	2,563
	Vested or expected to vest at March 31, 2014		5,472,476		$	4.62		5.41	$	2,283
	Exercisable at March 31, 2014		3,514,704		$	5.18		4.38	$	1,323
	Available for grant at March 31, 2014		1,792,053
	Other information concerning stock options are as follows:
		Three Months Ended
		March 31,
		2014			2013
	Weighted average fair value of stock options granted	$	1.84		$	1.72
	Aggregate intrinsic value of stock options exercised		51			14
	The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value of outstanding stock options for which the fair market value of the underlying common stock exceeds the respective stock option exercise price.
	Restricted Stock Awards
	During the first quarter of 2014, the Company granted 145,000 shares of restricted stock with a weighted-average grant date fair value of $3.78 which vest over a three year period. As of March 31, 2014, there was $822 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 1.59 years.
	For the three months ended March 31, 2014 and 2013, the Company recognized stock-based compensation as follows:
		Three Months Ended
		March 31,
		2014			2013
	Stock-based compensation:
	Costs of processing and distribution	$	33		$	33
	Marketing, general and administrative		442			437
	Research and development		15			15
	Total	$	490		$	485

Net_Loss_Income_Per_Common_Sha

Net (Loss) Income Per Common Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net (Loss) Income Per Common Share	'
	5. Net (Loss) Income Per Common Share
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted net (loss) income per common share is presented below:
		Three Months Ended
		March 31,
		2014		2013
	Basic shares		56,451,646		56,022,389
	Effect of dilutive securities:
	Stock options		—		267,721
	Diluted shares		56,451,646		56,290,110
	For the three months ended March 31, 2014 and 2013, approximately 4,214,548 and 3,822,000, respectively, of issued stock options were not included in the computation of diluted net income or loss per common share because they were anti-dilutive since their exercise price exceeded their market price. For the three months ended March 31, 2014, options to purchase 282,606 shares of common stock were not included in the computation of diluted earnings per share because dilutive shares are not factored into the calculation of earnings per share when a net loss is reported.
	For the three months ended March 31, 2014, 50,000 shares of convertible preferred stock were anti-dilutive on an as if-converted basis and were not included in the computation of diluted net loss per common share.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	6. Inventories
	Inventories by stage of completion are as follows:
		March 31,		December 31,
		2014		2013
	Unprocessed tissue and raw materials	$	31,486	$	31,468
	Tissue and work in process		41,111		39,417
	Implantable tissue and finished goods		29,824		33,102
	Supplies		2,125		2,139
		$	104,546	$	106,126
	For the three months ended March 31, 2014 and 2013, the Company had inventory write-downs of $1,314 and $757, respectively, relating primarily to product obsolescence.

Property_Plant_and_Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	7. Property, Plant and Equipment
	Property, plant and equipment are as follows:
		March 31,			December 31,
		2014			2013
	Land	$	2,617		$	2,618
	Buildings and improvements		49,876			50,106
	Processing equipment		44,475			43,309
	Surgical instruments		6,275			5,012
	Office equipment, furniture and fixtures		4,020			3 ,994
	Computer equipment and software		6,629			6,152
	Construction in process		17,421			16,156
	Equipment under capital leases:
	Processing equipment		396			396
	Computer equipment		744			744
	Office equipment		152			152
			132,605			128,639
	Less accumulated depreciation		(56,348	)		(53,901	)
		$	76,257		$	74,738
	Depreciation expense of property, plant and equipment was $2,536 and $1,503 for the three months ended March 31, 2014 and 2013, respectively.

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	8. Goodwill
		March 31,		December 31,
		2014		2013
	Balance at January 1	$	54,887	$	2,062
	Goodwill acquired during the period		—		52,825
		$	54,887	$	54,887

Other_Intangible_Assets

Other Intangible Assets	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Other Intangible Assets	'
	9. Other Intangible Assets
	Other intangible assets are as follows:
		March 31, 2014				December 31, 2013
		Gross				Gross
		Carrying		Accumulated		Carrying		Accumulated
		Amount		Amortization		Amount		Amortization
	Patents	$	10,726	$	2,103	$	10,637	$	1,935
	Acquired exclusivity rights		2,941		2,879		2,941		2,787
	Acquired licensing rights		10,850		5,629		10,850		5,326
	Marketing and procurement intangible assets		21,398		2,517		22,098		2,692
	Total	$	45,915	$	13,128	$	46,526	$	12,740
	Marketing and procurement intangible assets include the following: procurement contracts, trademarks, selling and marketing relationships, customer lists and non-compete agreements.
	Amortization expense of other intangible assets for the three months ended March 31, 2014 and 2013 was $1,128 and $525, respectively. At March 31, 2014, management’s estimates of future amortization expense for the next five years are as follows:
		Amortization
		Expense
	2014	$	3,300
	2015		4,000
	2016		3,400
	2017		3,300
	2018		3,300
		$	17,300

Other_Assets

Other Assets	3 Months Ended
	Mar. 31, 2014
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Assets	'
	10. Other Assets
	Other assets are as follows:
		March 31,		December 31,
		2014		2013
	Indemnification asset	$	13,000	$	13,000
	Other		1,228		1,332
		$	14,228	$	14,332
	Other assets include $13,000 of indemnification assets recognized on the date of the acquisition of Pioneer. Under the acquisition agreement, Pioneer deposited $13,000 in an escrow account and indemnified the Company for up to $13,000 for various outstanding legal issues. In conjunction with recording the indemnification asset, the Company also recorded a corresponding $13,000 indemnification liability.
	For the three months ended March 31, 2014 and 2013, the Company recognized interest expense associated with the amortization of its debt issuance costs which are included in Other in the table above of $35 and $4, respectively.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2014
Other Liabilities Disclosure [Abstract]	'
Accrued Expenses	'
	11. Accrued Expenses
	Accrued expenses are as follows:
		March 31,		December 31,
		2014		2013
	Accrued compensation	$	5,244	$	3,817
	Accrued donor recovery fees		4,418		5,771
	Accrued restructuring charges		1,564		2,609
	Accrued distributor commissions		1,636		2,059
	Accrued taxes		160		200
	Contingent consideration		39		39
	Other		7,574		7,983
		$	20,635	$	22,478
	The Company accrues for the estimated donor recovery fees due to third party recovery agencies as tissue is received.

Short_and_LongTerm_Obligations

Short and Long-Term Obligations	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Short and Long-Term Obligations	'
	12. Short and Long-Term Obligations
	Short and long-term obligations are as follows:
		March 31,			December 31,
		2014			2013
	Term loan	$	60,000		$	60,000
	Credit facilities		14,148			8,911
	Capital leases		119			139
	Total		74,267			69,050
	Less current portion		(4,073	)		(1,344	)
	Long-term portion	$	70,194		$	67,706
	On July 16, 2013, the Company obtained from TD Bank and Regions Bank, a 5 year, $80,000 senior secured facility, which includes a $60,000 term loan and a $20,000 revolving credit facility, that matures on July 16, 2018 with a variable interest rate between 100 and 300 basis points in excess of the one month LIBOR rate. At March 31, 2014, the interest rate for the term loan and revolving credit facility is 2.40%. The facility is secured by substantially all the assets of the Company and its subsidiaries and guaranteed by the Company’s domestic subsidiaries, other than RTIDS. The $20,000 revolving credit facility replaced the Company’s previous $15,000 U.S. credit facility. As of March 31, 2014, there was $12,250 outstanding on the revolving credit facility with TD Bank and Regions Bank. The term loan facility includes an interest only period of September 30, 2013 through December 31, 2014 with a final balloon principal payment at the end of the loan agreement. The new credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, payment of dividends, require a minimum cash balance on hand of $10,000 and require certain financial covenant ratios.
	In addition to the credit facility with TD Bank and Regions Bank, the Company has three credit facilities with German banks as of March 31, 2014. Under the terms of the revolving credit facilities with three German banks, the Company may borrow up to 1,700 Euro, or approximately $2,338, for working capital needs. The 1,000 Euro revolving credit facility is secured by a mortgage on the Company’s German facility. The 500 Euro revolving credit facility is secured by accounts receivable of the Company’s German subsidiary. The 200 Euro revolving credit facility is unsecured. The current interest rates for these lines of credit vary from 3.30% to 4.43%. As of March 31, 2014, there was $1,898 outstanding on revolving credit facilities with German banks.
	The total available credit on the Company’s four revolving credit facilities at March 31, 2014 was $10,189. The Company was in compliance with all covenants related to its revolving credit facilities as of March 31, 2014.
	The Company has capital leases with interest rates ranging from 1.49% to 8.46% and maturity dates through 2017. The $119 representing future maturities of capital leases includes interest in the amount of $3 at March 31, 2014. The present value of minimum lease payments as of March 31, 2014 was $116.
	As of March 31, 2014, contractual maturities of long-term obligations are as follows:
		Term Loan			Credit			Capital		Total
					Facilities			Leases
	2014	$	625		$	1,898		$	50	$	2,573
	2015		5,250			—			39		5,289
	2016		4,500			—			26		4,526
	2017		5,250			—			4		5,254
	2018 and beyond		44,375			12,250			—		56,625
		$	60,000		$	14,148		$	119	$	74,267

Other_LongTerm_Liabilities

Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Other Long-Term Liabilities	'
	13. Other Long-Term Liabilities
	Other long-term liabilities are as follows:
		March 31,		December 31,
		2014		2013
	Indemnification liability	$	13,000	$	13,000
	Other		239		446
		$	13,239	$	13,446
	As described in Note 10, the Company recorded a $13,000 indemnification liability on the date of the acquisition of Pioneer.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	14. Income Taxes
	The Company expects its deferred tax assets of $31,467, net of the valuation allowance at March 31, 2014 of $469, to be realized through the generation of future taxable income and the reversal of existing taxable temporary differences.
	Valuation allowances are established when necessary to reduce deferred tax assets to amounts which are more likely than not to be realized. As such, valuation allowances of $469 have been established at both March 31, 2014 and December 31, 2013, against a portion of the Company’s deferred tax assets relating to certain state net operating loss carryforwards.
	U.S. income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries. It is not practicable to estimate the amount of tax that might be payable. The Company’s intention is to permanently reinvest earnings in its foreign subsidiaries.
	As of March 31, 2014, the Company’s deferred tax assets were primarily attributable to U.S. federal net operating loss and credit carryforwards. The Company evaluates the need for deferred tax asset valuation allowances based on a more likely than not standard. The ability to realize deferred tax assets depends on the ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction.
	The assessment regarding whether a valuation allowance is required or should be adjusted also considers all available positive and negative evidence factors. It is difficult to conclude a valuation allowance is not required when there is significant objective and verifiable negative evidence, such as cumulative losses in recent years. The Company utilizes a rolling three years of actual results as the primary measure of cumulative losses in recent years.
	When evaluating whether the Company has overcome the significant negative evidence that resulted from cumulative losses in recent years, the Company adjusted its historical loss for items that the Company determined were not indicative of its ability to generate taxable income in future years. The Company is in a cumulative income position after adjusting for the items that were not indicative of its ability to generate taxable income in future years. The Company considers this objectively verifiable evidence that its current operations existing on March 31, 2014 have consistently demonstrated the ability to operate at a profit. The Company believes that this evidence is sufficient to overcome the unadjusted cumulative losses in recent years.
	The Company has a history of utilizing 100 percent of its deferred taxes assets before they expire and the forecasts of taxable earnings project a complete realization of all federal deferred tax assets before they expire, including under stressed scenarios.
	Upon considering all of the available positive and negative evidence, and the extent to which that evidence was objectively verifiable, the Company determined that the positive evidence outweighed the negative evidence and the deferred tax assets are more-likely-than-not realizable, as of March 31, 2014.
	The Company will continue to regularly assess the realizability of our deferred tax assets. Changes in historical earnings performance and future earnings projections, among other factors, may cause the Company to adjust its valuation allowance, which would impact the Company’s income tax expense in the period the Company determines that these factors have changed.
	The Company completed an examination during the three months ended March 31, 2014 by the Internal Revenue Service (“IRS”). The IRS examination covered the 2010 tax year and resulted in no material adjustments. In addition, one of the Company’s foreign subsidiaries is undergoing an examination by the German tax authorities. The foreign examination covers the foreign subsidiary’s 2006 through 2009 tax years.

Preferred_Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Preferred Stock	'
	15. Preferred Stock
	Preferred stock is as follows:
		March 31,			December 31,
		2014			2013
	Preferred shares issuance	$	50,000		$	50,000
	Preferred shares issuance costs		(1,290	)		(1,290	)
	Net proceeds		48,710			48,710
	Amortization of preferred shares issuance costs		123			77
	Accrued dividend payable		1,500			750
		$	50,333		$	49,537
	On June 12, 2013, the Company and Water Street entered into an investment agreement. Pursuant to the terms of the investment agreement, the Company agreed to issue $50,000 of convertible preferred equity to Water Street in a private placement which closed on July 16, 2013.

Restructuring_Charges

Restructuring Charges	3 Months Ended
	Mar. 31, 2014
Restructuring And Related Activities [Abstract]	'
Restructuring Charges	'
	16. Restructuring Charges
	The Company instituted a restructuring plan primarily related to termination of employees and a location closure as a result of the integration activities following the acquisition of Pioneer, which resulted in $2,881 of expenses for the year ended December 31, 2013. The total estimated restructuring charges should be paid in full prior to February 28, 2015. Severance payments are made to terminated employees over periods ranging from one month to twelve months and will not have a material impact on cash flows of the Company in any quarterly period. The following table includes a rollforward of restructuring charges included in accrued expenses, see Note 11.
	Accrued restructuring charges at January 1, 2014	$	2,609
	Cash payments		(1,045	)
	Accrued restructuring charges at March 31, 2014	$	1,564

Legal_Actions

Legal Actions	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Legal Actions	'
	17. Legal Actions
	The Company is, from time to time, involved in litigation relating to claims arising out of its operations in the ordinary course of business. The Company believes that none of these claims that were outstanding as of March 31, 2014 will have a material adverse impact on its financial position or results of operations.
	Biomedical Tissue Service, Ltd.(“BTS”)—The Company was named as a party, along with a number of other recovery and processor defendants, in lawsuits relating to the tissue recovery practices of BTS, an unaffiliated recovery agency. The company settled a majority of the BTS cases in 2012. The remaining cases were settled in 2013 for a payment of $2,700 with a contingent interest in any recovery in the Company’s litigation with its insurer, in the amount of $300. Accordingly, the Company recorded a litigation settlement charge of $3,000 in the second quarter of 2013.
	Lanx, Inc.(“Lanx”)—Lanx, a subsidiary of Biomet, Inc. filed suit in the second quarter of 2013 against Pioneer in the U.S. District Court, District of Colorado, alleging that one of the Company’s medical devices infringes certain of Lanx’s U.S. intellectual property rights, and seeking monetary damages and threatening injunctive relief. In the first quarter of 2014, the parties had reached an agreement in principle to resolve the claim with no material financial impact to the Company or its operations. Final documentation of the resolution is presently being negotiated. The Company has given notice to the former Pioneer stockholders’ agent of an indemnification claim against the Pioneer escrow fund for the financial implications of the agreement.
	Coloplast—The Company is presently named as co-defendant along with other companies in a small number of the transvaginal surgical mesh (“TSM”) mass tort claims being brought in various state and federal courts. The TSM litigation has as its catalyst various Public Health Notifications issued by the U.S. Food and Drug Administration (“FDA”) with respect to the placement of certain TSM implants that were the subject of 510k regulatory clearance prior to their distribution. The Company does not process or otherwise manufacture for distribution in the U.S. any implants that were the subject of these FDA Public Health Notifications. The Company denies any allegations against it and intends to vigorously defend itself.
	In addition to claims made directly against the Company, Coloplast, a distributor of TSM’s and certain allografts processed and private labeled for them under a contract with the Company, has also been named as a defendant in individual TSM cases in various federal and state courts around the U.S. Coloplast has requested that the Company indemnify or defend Coloplast in those claims which allege injuries caused only by the Company’s allograft implants. If, following a formal request for defense and indemnification by Coloplast in accordance with the terms and conditions of the applicable contracts, the Company either determines such indemnification and defense to be required by the Company, or if such defense and indemnification are assumed under a reservation of rights by the Company, as may be applicable, it is anticipated that such defense and indemnification will be afforded coverage under the Company’s insurance policy subject to a reservation of rights by our insurer.
	Based on the current information available to the Company, it is not possible to evaluate and estimate with reasonable certainty the impact that current or any future TSM litigation may have on the Company.
	The Company’s accounting policy is to accrue for legal costs as they are incurred.

Segment_Data

Segment Data	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Data	'
	18. Segment Data
	The Company distributes natural tissues, metals and synthetic implants through various distribution channels. The Company operates in one reportable segment comprised of six lines of business. The Company’s six lines of business are comprised of: spine, sports medicine, bone graft substitutes (“BGS”) and general orthopedic, ortho fixation, surgical specialties and dental. Discrete financial information is not available for these six lines of business. The following table presents revenues from these six categories and other revenues for the three months ended March 31, 2014 and 2013, respectively:
		Three Months Ended
		March 31,
		2014			2013
		(In Thousands)
	Revenues:
	Spine	$	19,063		$	10,099
	Sports medicine		11,360			10,511
	BGS and general orthopedic		8,147			5,351
	Ortho fixation		7,495			—
	Surgical specialties		7,278			6,954
	Dental		4,646			4,173
	Other revenues		2,756			3,334
	Total revenues	$	60,745		$	40,422
	Domestic revenues		54,815			36,114
	International revenues		5,930			4,308
	Total revenues	$	60,745		$	40,422
	The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution:
		Three Months Ended
		March 31,
		2014			2013
	Percent of revenues derived from:
	Distributor
	Zimmer, Inc.		17	%		12	%
	Medtronic, Inc.		14	%		20	%
	Davol, Inc.		7	%		12	%
	International		10	%		11	%
	The following table presents property, plant and equipment—net by significant geographic location:
		March 31,			December 31,
		2014			2013
	Property, plant and equipment—net:
	Domestic	$	60,376		$	58,458
	International		15,881			16,280
	Total	$	76,257		$	74,738

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	19. Subsequent Events
	The Company evaluated subsequent events as of the issuance date of the condensed consolidated financial statements as defined by FASB ASC 855 Subsequent Events, and identified no subsequent events that require adjustment to, or disclosure of, in these condensed consolidated financial statements.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	The condensed consolidated financial statements include the accounts of RTI Surgical, Inc. and its wholly owned subsidiaries, Pioneer Surgical Technology, Inc. (“Pioneer”), Tutogen Medical, Inc. (“TMI”), RTI Surgical, Inc. – Cardiovascular (inactive), Biological Recovery Group, Inc. (inactive) and RTI Services, Inc. (inactive). The condensed consolidated financial statements also include the accounts of RTI Donor Services, Inc. (“RTIDS”), which is a controlled entity.

Merger_with_Pioneer_Surgical_T1

Merger with Pioneer Surgical Technology, Inc. (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Summary of Purchase Price	'
	The purchase price was financed as follows:
	Cash proceeds from term loan	$	60,000
	Net cash proceeds from preferred share issuance		48,710
	Cash from RTI Surgical		17,597
	Total purchase price	$	126,307
Allocation of Total Consideration of Tangible and Intangible Assets and Liabilities	'
	The table below represents an allocation of the total consideration to Pioneer’s tangible and intangible assets and liabilities based on management’s preliminary estimate of their respective fair values as of July 16, 2013.
	Inventories	$	35,972
	Accounts receivable		10,567
	Other current assets		6,059
	Property, plant and equipment		15,258
	Other assets		13,260
	Current liabilities		(10,893	)
	Other long-term liabilities		(19,841	)
	Net tangible assets acquired		50,382
	Other intangible assets		23,100
	Goodwill		52,825
	Total net assets acquired	$	126,307
Unaudited Pro Forma Information of Company's Operations	'
	The following unaudited pro forma information shows the results of the Company’s operations as though the acquisition had occurred as of the beginning of that period (in thousands, except per share data):
		For the Three
		Months Ended
		March 31, 2013
	Revenues	$	62,450
	Net income		477
	Basic net income per share		0.01
	Diluted net income per share		0.01

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Options Outstanding, Exercisable and Available for Grant	'
	Stock options outstanding, exercisable and available for grant at March 31, 2014 are summarized as follows:
		Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life (Years)
	Outstanding at January 1, 2014		5,518,604		$	4.63
	Granted		913,500			3.78
	Exercised		(90,500	)		3.23
	Forfeited or expired		(98,500	)		5.28
	Outstanding at March 31, 2014		6,243,104		$	4.51		5.87	$	2,563
	Vested or expected to vest at March 31, 2014		5,472,476		$	4.62		5.41	$	2,283
	Exercisable at March 31, 2014		3,514,704		$	5.18		4.38	$	1,323
	Available for grant at March 31, 2014		1,792,053
Other Information Concerning Stock Options	'
	Other information concerning stock options are as follows:
		Three Months Ended
		March 31,
		2014			2013
	Weighted average fair value of stock options granted	$	1.84		$	1.72
	Aggregate intrinsic value of stock options exercised		51			14
Stock-Based Compensation Recognized	'
	For the three months ended March 31, 2014 and 2013, the Company recognized stock-based compensation as follows:
		Three Months Ended
		March 31,
		2014			2013
	Stock-based compensation:
	Costs of processing and distribution	$	33		$	33
	Marketing, general and administrative		442			437
	Research and development		15			15
	Total	$	490		$	485

Net_Loss_Income_Per_Common_Sha1

Net (Loss) Income Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Reconciliation of Common Stock Used in Calculation of Basic and Diluted Earnings Per Share	'
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted net (loss) income per common share is presented below:
		Three Months Ended
		March 31,
		2014		2013
	Basic shares		56,451,646		56,022,389
	Effect of dilutive securities:
	Stock options		—		267,721
	Diluted shares		56,451,646		56,290,110

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Components of Inventories	'
	Inventories by stage of completion are as follows:
		March 31,		December 31,
		2014		2013
	Unprocessed tissue and raw materials	$	31,486	$	31,468
	Tissue and work in process		41,111		39,417
	Implantable tissue and finished goods		29,824		33,102
	Supplies		2,125		2,139
		$	104,546	$	106,126

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property Plant And Equipment [Abstract]	'
Components of Property, Plant and Equipment	'
	Property, plant and equipment are as follows:
		March 31,			December 31,
		2014			2013
	Land	$	2,617		$	2,618
	Buildings and improvements		49,876			50,106
	Processing equipment		44,475			43,309
	Surgical instruments		6,275			5,012
	Office equipment, furniture and fixtures		4,020			3 ,994
	Computer equipment and software		6,629			6,152
	Construction in process		17,421			16,156
	Equipment under capital leases:
	Processing equipment		396			396
	Computer equipment		744			744
	Office equipment		152			152
			132,605			128,639
	Less accumulated depreciation		(56,348	)		(53,901	)
		$	76,257		$	74,738

Goodwill_Tables

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
		March 31,		December 31,
		2014		2013
	Balance at January 1	$	54,887	$	2,062
	Goodwill acquired during the period		—		52,825
		$	54,887	$	54,887

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Components of Other Intangible Assets	'
	Other intangible assets are as follows:
		March 31, 2014				December 31, 2013
		Gross				Gross
		Carrying		Accumulated		Carrying		Accumulated
		Amount		Amortization		Amount		Amortization
	Patents	$	10,726	$	2,103	$	10,637	$	1,935
	Acquired exclusivity rights		2,941		2,879		2,941		2,787
	Acquired licensing rights		10,850		5,629		10,850		5,326
	Marketing and procurement intangible assets		21,398		2,517		22,098		2,692
	Total	$	45,915	$	13,128	$	46,526	$	12,740
Estimates of Future Amortization Expense	'
	March 31, 2014 and 2013 was $1,128 and $525, respectively. At March 31, 2014, management’s estimates of future amortization expense for the next five years are as follows:
		Amortization
		Expense
	2014	$	3,300
	2015		4,000
	2016		3,400
	2017		3,300
	2018		3,300
		$	17,300

Other_Assets_Tables

Other Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Schedule of Other Assets	'
	Other assets are as follows:
		March 31,		December 31,
		2014		2013
	Indemnification asset	$	13,000	$	13,000
	Other		1,228		1,332
		$	14,228	$	14,332

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2014
Other Liabilities Disclosure [Abstract]	'
Accrued Expenses	'
	Accrued expenses are as follows:
		March 31,		December 31,
		2014		2013
	Accrued compensation	$	5,244	$	3,817
	Accrued donor recovery fees		4,418		5,771
	Accrued restructuring charges		1,564		2,609
	Accrued distributor commissions		1,636		2,059
	Accrued taxes		160		200
	Contingent consideration		39		39
	Other		7,574		7,983
		$	20,635	$	22,478

Short_and_LongTerm_Obligations1

Short and Long-Term Obligations (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Short and Long-Term Obligations	'
	Short and long-term obligations are as follows:
		March 31,			December 31,
		2014			2013
	Term loan	$	60,000		$	60,000
	Credit facilities		14,148			8,911
	Capital leases		119			139
	Total		74,267			69,050
	Less current portion		(4,073	)		(1,344	)
	Long-term portion	$	70,194		$	67,706
Contractual Maturities of Short and Long-Term Obligations	'
	As of March 31, 2014, contractual maturities of long-term obligations are as follows:
		Term Loan			Credit			Capital		Total
					Facilities			Leases
	2014	$	625		$	1,898		$	50	$	2,573
	2015		5,250			—			39		5,289
	2016		4,500			—			26		4,526
	2017		5,250			—			4		5,254
	2018 and beyond		44,375			12,250			—		56,625
		$	60,000		$	14,148		$	119	$	74,267

Other_LongTerm_Liabilities_Tab

Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Text Block [Abstract]	'
Schedule of Other Long-Term Liabilities	'
	Other long-term liabilities are as follows:
		March 31,		December 31,
		2014		2013
	Indemnification liability	$	13,000	$	13,000
	Other		239		446
		$	13,239	$	13,446

Preferred_Stock_Tables

Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Schedule of Preferred Stock	'
	Preferred stock is as follows:
		March 31,			December 31,
		2014			2013
	Preferred shares issuance	$	50,000		$	50,000
	Preferred shares issuance costs		(1,290	)		(1,290	)
	Net proceeds		48,710			48,710
	Amortization of preferred shares issuance costs		123			77
	Accrued dividend payable		1,500			750
		$	50,333		$	49,537

Restructuring_Charges_Tables

Restructuring Charges (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring And Related Activities [Abstract]	'
Schedule of Restructuring Charges	'
	The following table includes a rollforward of restructuring charges included in accrued expenses, see Note 11.
	Accrued restructuring charges at January 1, 2014	$	2,609
	Cash payments		(1,045	)
	Accrued restructuring charges at March 31, 2014	$	1,564

Segment_Data_Tables

Segment Data (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Revenues from Tissue Distribution and Other Revenues	'
	The following table presents revenues from these six categories and other revenues for the three months ended March 31, 2014 and 2013, respectively:
		Three Months Ended
		March 31,
		2014			2013
		(In Thousands)
	Revenues:
	Spine	$	19,063		$	10,099
	Sports medicine		11,360			10,511
	BGS and general orthopedic		8,147			5,351
	Ortho fixation		7,495			—
	Surgical specialties		7,278			6,954
	Dental		4,646			4,173
	Other revenues		2,756			3,334
	Total revenues	$	60,745		$	40,422
	Domestic revenues		54,815			36,114
	International revenues		5,930			4,308
	Total revenues	$	60,745		$	40,422
Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution	'
	The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution:
		Three Months Ended
		March 31,
		2014			2013
	Percent of revenues derived from:
	Distributor
	Zimmer, Inc.		17	%		12	%
	Medtronic, Inc.		14	%		20	%
	Davol, Inc.		7	%		12	%
	International		10	%		11	%
Schedule of Property, Plant and Equipment - Net by Significant Geographic Location	'
	The following table presents property, plant and equipment—net by significant geographic location:
		March 31,			December 31,
		2014			2013
	Property, plant and equipment—net:
	Domestic	$	60,376		$	58,458
	International		15,881			16,280
	Total	$	76,257		$	74,738

Operations_and_Organization_Ad

Operations and Organization - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
	State
	Country
Operations And Organization [Line Items]	'
Number of states that receive distribution	50
Number of countries that receive distribution	45
Alachua, Florida [Member]	'
Operations And Organization [Line Items]	'
Number of operating facilities	2
Neunkirchen, Germany [Member]	'
Operations And Organization [Line Items]	'
Number of operating facilities	1

Merger_with_Pioneer_Surgical_T2

Merger with Pioneer Surgical Technology, Inc. - Additional Information (Detail) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Jul. 16, 2013

Dec. 31, 2012

Jul. 16, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

In Thousands, unless otherwise specified

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Senior Secured Facility [Member]

Bank Term Loan [Member]

Revolving Credit Facility [Member]

Convertible Preferred Stock [Member]

Minimum [Member]

Maximum [Member]

Operating Segments [Member]

Senior Secured Facility [Member]

Senior Secured Facility [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition agreement date

'

'

'

'

'

12-Jun-13

'

'

'

'

'

'

'

Business acquisition cash consideration

'

'

'

'

$126,307

'

'

'

'

'

'

'

'

Business acquisition date

'

'

'

'

'

16-Jul-13

'

'

'

'

'

'

'

Term of senior secured credit facility

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

Amount of senior secured facility obtained

'

'

'

'

'

80,000

'

60,000

20,000

'

'

'

'

Maturity date of senior secured credit facility

'

'

'

'

'

'

16-Jul-18

'

'

'

'

'

'

Variable interest rate, basis point

'

'

'

'

'

'

'

'

'

'

1.00%

3.00%

'

Existing credit facility amount replaced by new revolving credit facility

'

'

'

'

'

15,000

'

'

'

'

'

'

'

Proceeds from issuance of convertible preferred stock

'

'

'

'

'

50,000

'

'

'

'

'

'

'

Convertible preferred stock dividend rate

'

'

'

'

'

'

'

'

'

6.00%

'

'

'

Financing cost and expense

'

'

'

'

'

1,989

'

'

'

'

'

'

'

Goodwill assigned to operating segment

54,887

54,887

52,825

2,062

'

'

'

'

'

'

'

'

52,825

Fair value of receivables

'

'

'

'

'

10,567

'

'

'

'

'

'

'

Contractual amount, gross

'

'

'

'

'

11,712

'

'

'

'

'

'

'

Uncollected amount

'

'

'

'

'

$1,145

'

'

'

'

'

'

'

Merger_with_Pioneer_Surgical_T3

Merger with Pioneer Surgical Technology, Inc. - Summary of Purchase Price (Detail) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Jul. 16, 2013
Business Combinations [Abstract]	'
Cash proceeds from term loan	$60,000
Net cash proceeds from preferred share issuance	48,710
Cash from RTI Surgical	17,597
Total purchase price	$126,307

Merger_with_Pioneer_Surgical_T4

Merger with Pioneer Surgical Technology, Inc. - Allocation of Total Consideration of Tangible and Intangible Assets and Liabilities (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Jul. 16, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Business Combinations [Abstract]	'	'	'	'
Inventories	'	'	$35,972	'
Accounts receivable	'	'	10,567	'
Other current assets	'	'	6,059	'
Property, plant and equipment	'	'	15,258	'
Other assets	'	'	13,260	'
Current liabilities	'	'	-10,893	'
Other long-term liabilities	'	'	-19,841	'
Net tangible assets acquired	'	'	50,382	'
Other intangible assets	'	'	23,100	'
Goodwill	54,887	54,887	52,825	2,062
Total net assets acquired	'	'	$126,307	'

Merger_with_Pioneer_Surgical_T5

Merger with Pioneer Surgical Technology, Inc. - Unaudited Pro Forma Information of Company's Operations (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2013
Business Combinations [Abstract]	'
Revenues	$62,450
Net income	$477
Basic net income per share	$0.01
Diluted net income per share	$0.01

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
	Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Contractual terms of stock options granted, in years	'10 years
Stock-based compensation plans, number	5
Percentage of market value of common stock, stock options exercise price	100.00%
Percentage of market value of common stock, restricted stock award granted	100.00%
Restricted Stock Awards [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock-based compensation award, vesting period	'3 years
Total unrecognized stock-based compensation	822
Weighted-average period recognized stock-based compensation	'1 year 7 months 2 days
Restricted stock granted during period	145,000
Weighted-average grant date fair value of restricted stock granted	3.78
Restricted Stock Awards [Member] | Minimum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock-based compensation award, vesting period	'1 year
Restricted Stock Awards [Member] | Maximum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock-based compensation award, vesting period	'3 years
Stock Options [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total unrecognized stock-based compensation	3,139
Weighted-average period recognized stock-based compensation	'3 years 6 months 26 days
Stock Options [Member] | Minimum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock-based compensation award, vesting period	'1 year
Stock Options [Member] | Maximum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Stock-based compensation award, vesting period	'5 years
1998 Stock Option Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares of common stock to be issued with respect to awards granted	4,406,400
2004 Equity Incentive Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares of common stock to be issued with respect to awards granted	2,000,000
2010 Equity Incentive Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares of common stock to be issued with respect to awards granted	5,000,000
TMI 1996 Stock Option Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares of common stock to be issued with respect to awards granted	4,880,000
TMI 2006 Incentive and Non Statutory Stock Option Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares of common stock to be issued with respect to awards granted	1,830,000

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Options Outstanding, Exercisable and Available for Grant (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Outstanding, Number of Shares	5,518,604
Granted, Number of Shares	913,500
Exercised, Number of Shares	-90,500
Forfeited or expired, Number of Shares	-98,500
Outstanding, Number of Shares	6,243,104
Vested or expected to vest, Number of Shares	5,472,476
Exercisable, Number of Shares	3,514,704
Available for grant, Number of Shares	1,792,053
Outstanding, Weighted Average Exercise Price	$4.63
Granted, Weighted Average Exercise Price	$3.78
Exercised, Weighted Average Exercise Price	$3.23
Forfeited or expired, Weighted Average Exercise Price	$5.28
Outstanding, Weighted Average Exercise Price	$4.51
Vested or expected to vest, Weighted Average Exercise Price	$4.62
Exercisable, Weighted Average Exercise Price	$5.18
Outstanding, Weighted Average Remaining Contractual Life (Years)	'5 years 10 months 13 days
Vested or expected to vest, Weighted Average Remaining Contractual Life (Years)	'5 years 4 months 28 days
Exercisable, Weighted Average Remaining Contractual Life (Years)	'4 years 4 months 17 days
Outstanding, Aggregate Intrinsic Value	$2,563
Vested or expected to vest, Aggregate Intrinsic Value	2,283
Exercisable, Aggregate Intrinsic Value	$1,323

StockBased_Compensation_Other_

Stock-Based Compensation - Other Information Concerning Stock Options (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Weighted average fair value of stock options granted	$1.84	$1.72
Aggregate intrinsic value of stock options exercised	$51	$14

StockBased_Compensation_StockB

Stock-Based Compensation - Stock-Based Compensation Recognized (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$490	$485
Costs of Processing and Distribution [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	33	33
Marketing, General and Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	442	437
Research and Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation	$15	$15

Net_Loss_Income_Per_Common_Sha2

Net (Loss) Income Per Common Share - Reconciliation of Common Stock Used in Calculation of Basic and Diluted Earnings Per Share (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Basic shares	56,451,646	56,022,389
Effect of dilutive securities:	'	'
Stock options	'	267,721
Diluted shares	56,451,646	56,290,110

Net_Loss_Income_Per_Common_Sha3

Net (Loss) Income Per Common Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive stock excluded from the computation of diluted EPS	50,000	'
Common Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive stock excluded from the computation of diluted EPS	282,606	'
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive stock excluded from the computation of diluted EPS	4,214,548	3,822,000

Inventories_Components_of_Inve

Inventories - Components of Inventories (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Unprocessed tissue and raw materials	$31,486	$31,468
Tissue and work in process	41,111	39,417
Implantable tissue and finished goods	29,824	33,102
Supplies	2,125	2,139
Inventory - net	$104,546	$106,126

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Inventory Disclosure [Abstract]	'	'
Inventory write-downs	$1,314	$757

Property_Plant_and_Equipment_C

Property, Plant and Equipment - Components of Property, Plant and Equipment (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$132,605	$128,639
Less accumulated depreciation	-56,348	-53,901
Property, plant and equipment, net	76,257	74,738
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	2,617	2,618
Building And Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	49,876	50,106
Processing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	44,475	43,309
Surgical Instruments [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	6,275	5,012
Office Equipment, Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	4,020	3,994
Computer Equipment and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	6,629	6,152
Construction in Process [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	17,421	16,156
Capital Leased Processing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	396	396
Capital Leased Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	744	744
Capital Leased Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$152	$152

PropertyPlant_and_Equipment_Ad

Property,Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Property Plant And Equipment [Abstract]	'	'
Depreciation expense of property, plant and equipment	$2,536	$1,503

Goodwill_Goodwill_Detail

Goodwill - Goodwill (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Jul. 16, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'
Beginning Balance, Goodwill	$54,887	$2,062	$52,825
Goodwill acquired during the year	'	52,825	'
Ending Balance, Goodwill	$54,887	$54,887	$52,825

Other_Intangible_Assets_Compon

Other Intangible Assets - Components of Other Intangible Assets (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$45,915	$46,526
Accumulated Amortization	13,128	12,740
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	10,726	10,637
Accumulated Amortization	2,103	1,935
Acquired Exclusivity Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	2,941	2,941
Accumulated Amortization	2,879	2,787
Acquired Licensing Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	10,850	10,850
Accumulated Amortization	5,629	5,326
Marketing and Procurement Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	21,398	22,098
Accumulated Amortization	$2,517	$2,692

Other_Intangible_Assets_Additi

Other Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
Amortization expense of other intangible assets	$1,128	$525

Other_Intangible_Assets_Estima

Other Intangible Assets - Estimates of Future Amortization Expense (Detail) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
2014	$3,300
2015	4,000
2016	3,400
2017	3,300
2018	3,300
Total future amortization expense	$17,300

Other_Assets_Schedule_of_Other

Other Assets - Schedule of Other Assets (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Indemnification asset	$13,000	$13,000
Other	1,228	1,332
Total other assets	$14,228	$14,332

Other_Assets_Additional_Inform

Other Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'	'
Indemnification asset	$13,000	'	$13,000
Deposited in escrow account	13,000	'	'
Indemnification liability	13,000	'	13,000
Interest expense associated with the amortization of debt issuance costs	$35	$4	'

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Accrued compensation	$5,244	$3,817
Accrued donor recovery fees	4,418	5,771
Accrued restructuring charges	1,564	2,609
Accrued distributor commissions	1,636	2,059
Accrued taxes	160	200
Contingent consideration	39	39
Other	7,574	7,983
Total accrued expenses	$20,635	$22,478

Short_and_LongTerm_Obligations2

Short and Long-Term Obligations - Short and Long-Term Obligations (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Term loan	$60,000	$60,000
Credit facilities	14,148	8,911
Capital leases	119	139
Debt and capital lease obligation, total	74,267	69,050
Less current portion	-4,073	-1,344
Long-term portion	$70,194	$67,706

Short_and_LongTerm_Obligations3

Short and Long-Term Obligations - Additional Information (Detail)

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

0 Months Ended

In Thousands, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jul. 16, 2013

Jul. 16, 2013

Jul. 16, 2013

Jul. 16, 2013

Jul. 16, 2013

Jul. 16, 2013

USD ($)

USD ($)

Credit Facilities [Member]

Capital Leases [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

USD ($)

USD ($)

USD ($)

EUR (€)

Revolving Credit Facility [Member]

Credit Facilities [Member]

Secured by Mortgage [Member]

Secured by Accounts Receivable [Member]

USD ($)

USD ($)

Senior Secured Facility [Member]

Bank Term Loan [Member]

Revolving Credit Facility [Member]

Minimum [Member]

Maximum [Member]

Debt_Instruments

USD ($)

Debt_Instruments

EUR (€)

EUR (€)

USD ($)

USD ($)

Senior Secured Facility [Member]

Senior Secured Facility [Member]

Standby Letters of Credit [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of senior secured credit facility

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

Amount of senior secured facility obtained

'

'

'

'

'

'

'

'

'

'

'

$80,000

'

$60,000

$20,000

'

'

Maturity date of senior secured credit facility

'

'

'

'

'

'

'

'

'

'

'

'

16-Jul-18

'

'

'

'

Variable interest rate, basis point

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

3.00%

Existing credit facility amount replaced by new revolving credit facility

'

'

'

'

'

'

'

'

'

'

15,000

'

'

'

'

'

'

Credit outstanding

14,148

8,911

12,250

'

'

'

1,898

'

'

'

'

'

'

'

'

'

'

Variable interest rate base

'

'

'

'

'

'

'

'

'

'

'One month LIBOR rate

'

'

'

'

'

'

Revolving credit facility variable interest rate

'

'

'

'

'

'

'

'

'

'

2.40%

'

'

'

'

'

'

Minimum cash balance required for covenant compliance

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

Covenant Terms of Credit Facility

'

'

'

'

'

'

'

'

'

'

'The new credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, payment of dividends, require a minimum cash balance on hand of $10,000 and require certain financial covenant ratios

'

'

'

'

'

'

Long-term obligations outstanding, number

'

'

4

'

'

'

'

3

'

'

'

'

'

'

'

'

'

Credit facility, borrowing capacity

'

'

'

'

2,338

1,700

'

'

'

'

'

'

'

'

'

'

'

Credit facility, secured

'

'

'

'

'

'

'

'

1,000

500

'

'

'

'

'

'

'

Credit facility, unsecured amount

'

'

'

'

'

200

'

'

'

'

'

'

'

'

'

'

'

Minimum interest rates

'

'

'

1.49%

3.30%

3.30%

'

'

'

'

'

'

'

'

'

'

'

Maximum interest rates

'

'

'

8.46%

4.43%

4.43%

'

'

'

'

'

'

'

'

'

'

'

Credit facility, current borrowing capacity

'

'

10,189

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital leases maturity date

'2017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future maturities of capital leases

'

'

'

119

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest included in minimum lease payments

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Present value of minimum lease payments

$116

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short_and_LongTerm_Contractual

Short and Long-Term - Contractual Maturities of Short and Long-Term Obligations (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Short Term And Long Term Debt [Line Items]	'	'
2014	$2,573	'
2015	5,289	'
2016	4,526	'
2017	5,254	'
2018 and beyond	56,625	'
Debt and capital lease obligation, total	74,267	69,050
Term Loan [Member]	'	'
Schedule Of Short Term And Long Term Debt [Line Items]	'	'
2014	625	'
2015	5,250	'
2016	4,500	'
2017	5,250	'
2018 and beyond	44,375	'
Debt and capital lease obligation, total	60,000	'
Credit Facilities [Member]	'	'
Schedule Of Short Term And Long Term Debt [Line Items]	'	'
2014	1,898	'
2015	'	'
2016	'	'
2017	'	'
2018 and beyond	12,250	'
Debt and capital lease obligation, total	14,148	'
Capital Leases [Member]	'	'
Schedule Of Short Term And Long Term Debt [Line Items]	'	'
2014	50	'
2015	39	'
2016	26	'
2017	4	'
2018 and beyond	'	'
Debt and capital lease obligation, total	$119	'

Other_LongTerm_Liabilities_Sch

Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'	'
Indemnification liability	$13,000	$13,000
Other	239	446
Total other long-term liabilities	$13,239	$13,446

Other_LongTerm_Liabilities_Add

Other Long-Term Liabilities - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'	'
Indemnification liability	$13,000	$13,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]	'	'
Deferred tax assets	$31,467	'
Domestic deferred tax assets, valuation allowances	$469	$469
Primary measure of cumulative losses number of rolling years	'3 years	'
Percentage of utilization of deferred tax assets before expiration	100.00%	'
Domestic Tax Authority [Member]	'	'
Operating Loss Carryforwards [Line Items]	'	'
Income tax examination period	'2010	'
Minimum [Member] | Foreign Tax Authority [Member]	'	'
Operating Loss Carryforwards [Line Items]	'	'
Income tax examination period	'2006	'
Maximum [Member] | Foreign Tax Authority [Member]	'	'
Operating Loss Carryforwards [Line Items]	'	'
Income tax examination period	'2009	'

Preferred_Stock_Schedule_of_Pr

Preferred Stock - Schedule of Preferred Stock (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Temporary Equity [Line Items]	'	'
Preferred shares issuance	$50,333	$49,537
Preferred shares issuance costs	-1,290	-1,290
Net proceeds	48,710	48,710
Amortization of preferred shares issuance costs	123	77
Accrued dividend payable	1,500	750
Total	50,333	49,537
Series A Preferred Stock [Member]	'	'
Temporary Equity [Line Items]	'	'
Preferred shares issuance	50,000	50,000
Amortization of preferred shares issuance costs	$46	'

Preferred_Stock_Additional_Inf

Preferred Stock - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Jun. 12, 2013
In Thousands, unless otherwise specified			Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Private Placement with WSHP [Member]	Private Placement with WSHP [Member]
					Series A Preferred Stock [Member]	Series A Preferred Stock [Member]
Temporary Equity [Line Items]	'	'	'	'	'	'
Private placement of convertible preferred equity	$50,333	$49,537	$50,000	$50,000	'	$50,000
Convertible preferred equity private placement closing date	'	'	'	'	16-Jul-13	'

Restructuring_Charges_Addition

Restructuring Charges - Additional Information (Detail) (USD $)	12 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
		Minimum [Member]	Maximum [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'
Acquisition expenses	$2,881	'	'
Severance payment period	'	'1 month	'12 months

Restructuring_Charges_Schedule

Restructuring Charges - Schedule of Restructuring Charges (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Restructuring And Related Activities [Abstract]	'
Accrued restructuring charges, beginning balance	$2,609
Cash payments	-1,045
Accrued restructuring charges, ending balance	$1,564

Legal_Actions_Additional_Infor

Legal Actions - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'	'
Litigation settlement charge	$3,000	'
Contingent interest payable	'	300
Upfront payment of contingent interest	'	$2,700

Segment_Data_Additional_Inform

Segment Data - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
	Segment
Segment Reporting [Abstract]	'
Number of reportable segments	1
Number of business lines	6

Segment_Data_Revenues_from_Tis

Segment Data - Revenues from Tissue Distribution and Other Revenues (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Other revenues	$2,756	$3,334
Total revenues	60,745	40,422
Domestic [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues	54,815	36,114
International [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues	5,930	4,308
Spine [Member] | Tissue Distribution [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Tissue distribution	19,063	10,099
Sports Medicine [Member] | Tissue Distribution [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Tissue distribution	11,360	10,511
BGS and General Orthopedic [Member] | Tissue Distribution [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Tissue distribution	8,147	5,351
Ortho Fixation [Member] | Tissue Distribution [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Tissue distribution	7,495	'
Surgical Specialties [Member] | Tissue Distribution [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Tissue distribution	7,278	6,954
Dental [Member] | Tissue Distribution [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Tissue distribution	$4,646	$4,173

Segment_Data_Schedule_of_Perce

Segment Data - Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution (Detail) (Sales [Member])	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Zimmer, Inc. [Member]	'	'
Concentration Risk [Line Items]	'	'
Percentage of revenues	17.00%	12.00%
Medtronic, Inc. [Member]	'	'
Concentration Risk [Line Items]	'	'
Percentage of revenues	14.00%	20.00%
Davol, Inc. [Member]	'	'
Concentration Risk [Line Items]	'	'
Percentage of revenues	7.00%	12.00%
International Customers [Member]	'	'
Concentration Risk [Line Items]	'	'
Percentage of revenues	10.00%	11.00%

Segment_Data_Schedule_of_Prope

Segment Data - Schedule of Property, Plant and Equipment - Net by Significant Geographic Location (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment-net	$76,257	$74,738
Domestic [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment-net	60,376	58,458
International [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment-net	$15,881	$16,280